COST EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB AS A TREATMENT OPTION FOR PATIENTS WITH MULTIPLE SCLEROSIS IN GREECE

被引：1
|
作者：
Kourkoulas, N. [1 ]
Athanasakis, K. [1 ]
Kyriopoulos, J. [1 ]
机构：
[1] Natl Sch Publ Hlth, Athens, Greece
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2025
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND59
引用
收藏
页码：S339 / S339
页数：1
相关论文
共 50 条
  • [1] COST EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB AS A TREATMENT OPTION FOR PATIENTS WITH MULTIPLE SCLEROSIS IN CYPRUS
    Kourkoulas, N.
    Athanasakis, K.
    Theodorou, M.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2018, 21 : S340 - S340
  • [2] COST-EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN BULGARIA, 2016
    Djambazov, S.
    Vekov, T.
    VALUE IN HEALTH, 2017, 20 (05) : A193 - A193
  • [3] Alemtuzumab: a further option for treatment of multiple sclerosis
    Menge, T.
    Kieseier, B. C.
    Warnke, C.
    Aktas, O.
    Hartung, H. -P.
    NERVENARZT, 2012, 83 (04): : 487 - 501
  • [4] Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States
    Chirikov, Viktor
    Ma, Ingrid
    Joshi, Namita
    Patel, Dipen
    Smith, Alden
    Giambrone, Cindy
    Cornelio, Noelle
    Hashemi, Lobat
    VALUE IN HEALTH, 2019, 22 (02) : 168 - 176
  • [5] Multiple sclerosis treatment in Greece: Cost and benefit
    Karageorgiou, E. E.
    Sotirli, S.
    Giannoulis, C.
    Polyzoi, M.
    Tarla, P.
    Logiotatos, N.
    Papageorgiou, H.
    Karageorgiou, C. E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 281 - 281
  • [6] COST-EFFECTIVENESS OF ALEMTUZUMAB FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Kohn, Christine G.
    Costales, Victoria
    Coleman, Craig I.
    Young, Dan
    Limone, Brendan L.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (10) : 1413 - 1414
  • [7] COST-EFFECTIVENESS OF TERIFLUNOMIDE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN GREECE
    Gourzoulidis, G.
    Kourlaba, G.
    Andreadou, E.
    Karageorgiou, K.
    Maniadakis, N.
    VALUE IN HEALTH, 2018, 21 : S339 - S339
  • [8] Cost-Effectiveness Analysis of Multiple Sclerosis Treatment Approaches
    Hola, Martina
    Gajdos, Ondrej
    Kamensky, Vojtech
    Kubincova, Karolina
    ADVANCES IN DIGITAL HEALTH AND MEDICAL BIOENGINEERING, VOL 2, EHB-2023, 2024, 110 : 69 - 77
  • [9] Alemtuzumab for the treatment of multiple sclerosis
    Evan, Jennifer R.
    Bozkurt, Subutay B.
    Thomas, Nikita C.
    Bagnato, Francesca
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (03) : 323 - 334
  • [10] Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis
    Warnke, C.
    Kieseier, B. C.
    Zettl, U.
    Hartung, H-P.
    NERVENARZT, 2009, 80 (04): : 468 - 474
12345